2025 Webinar: Resmetirom & Semaglutide for MASH in 2025

Create Account

Availability

Registration Required

https://aasld.zoom.us/j/89806880420

Dec 16, 2025 12:00 PM - 1:00 PM ET

Cost

$0.00

Credit Offered

1 AMA PRA Category 1 Credit

Description
Learning Objectives
Faculty and Disclosures

This session will address MASLD/ MASH 2025 needs regarding available treatment options for MASLD including current and emerging therapies and latest recommendations from AASLD after the November Annual Meeting. There have been recent publications on “real world” use of resmetirom including observed rates of prescription coverage (81%), AE’s (41%), and patient adherence (84% at 6 mon) (Ravela Hep Comm 2025). These data demonstrate the need for protocolized monitoring of patients to achieve optimal treatment options. Furthermore, there are now early data presented on use of resmetirom for up to 3 years in non-cirrhotic MASH and 2 years in patients with MASH cirrhosis (Alkhouri EASL 2025). Lastly, semaglutide injections for 72 weeks have demonstrated promising safety & efficacy for F2/F3 MASH and is going to be reviewed for FDA approval in September 2025 (Sanyal NEJM 2025). It is anticipated that the AASLD will publish an updated guidance on MASLD management in the 4th Quarter of 2025. Therefore, there is a need to review currently available data for practitioners managing patients with non-cirrhotic MASH including resmetiron and semaglutide (pending FDA approval)

Upon completion of this course, participants should be able to:

• Identify available treatment options for MASLD including current and emerging therapies and latest recommendations

• Demonstrate the need for protocolized monitoring of patients to achieve optimal treatment options

• Review currently available data for practitioners managing patients with non-cirrhotic MASH including resmetiron and semaglutide (pending FDA approval)

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings